GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Daratumumab
Related studies linked through entity extraction aliases.
Daratumumab in Primary Antiphospholipid Syndrome
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
- Status
- RECRUITING
- Phase
- PHASE2
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
- Status
- TERMINATED
- Phase
- PHASE1
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Daratumumab
- Status
- RECRUITING
- Phase
- PHASE3
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1